Ask AI
Treating DLBCL

CME

Novel Agents, New Combinations: An Expert Overview of Unmet Needs and Emerging Therapies for DLBCL

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: January 30, 2026

Expiration: July 29, 2026

Activity

Progress
1 2
Course Completed

References

  1. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040-2045.
  2. Tilly H, Morschhauser F, Sehn LH, et al. The POLARIX study: polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2021;138(suppl 2):LBA1.
  3. Salles G, Morschhauser F, Sehn LHH, et al. Five-year analysis of the POLARIX study: prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes. Presented at: American Society of Hematology Annual Meeting 2025; December 8, 2024. Abstract 469.
  4. Calabretta E, Lu K, Zhao X, et al. The benefit of pola-R-CHP in DLBclass-defined molecular subsets of newly diagnosed DLBCL in the POLARIX trial. Presented at: International Conference on Malignant Lymphoma 2025; June 17-21, 2025. Abstract LBA1.
  5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: B-cell lymphomas. v1.2026. nccn.org. Accessed January 22, 2026.
  6. Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32:3490-3496.
  7. van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35:544-551.  
  8. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-4190.
  9. Locke F, Westin JR, Oluwole OO, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389:148-157.
  10. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294-2308.
  11. Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386:629-639.
  12. Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23:1066-1077.
  13. Nze C, Flowers C. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;1:382-385.
  14. Sehn LH, Kahl BS, Matasar MJ, et al. ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL). Presented at: American Society of Clinical Oncology Annual Meeting 2021; June 3-8, 2021. Abstract TPS7572.
  15. Argnani L, Broccoli A, Pellegrini C, et al. Real-world outcomes of relapsed/refractory diffuse large b-cell lymphoma treated with polatuzumab vedotin-based therapy. Hemasphere. 2022;6:e798.
  16. Duell J, Abrisqueta P, Andre M, et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study. Haematologica. 2024;109:553-566.
  17. Qualls DA, Lambert N, Caimi PF, et al. Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood. 2023;142:2327-2331.
  18. Abramson JS, Palomba ML, Gorden LI, et al. Five-year survival of patients (pts) from Transcend NHL 001 (TRANSCEND) supports curative potential of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Presented at: American Society of Hematology Annual Meeting 2024; December 7-10, 2024. Abstract 3125.
  19. Abramson J, Ku M, Fox C, et al. Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO. Presented at: American Society of Hematology Annual Meeting 2025; December 6-9, 2025. Abstract 5519.
  20. Matasar M, Li Z, Vassilakopoulos TP, et al. Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma. Presented at: European Hematology Association Annual Meeting 2025; June 13, 2025. Abstract S101.
  21. Westin J, Zhang H, Kim W, et al. Mosunetuzumab plus polatuzumab vedotin is superior to R-GemOx in transplant-ineligible patients with R/R LBCL: primary results of the phase III SUNMO trial. Presented at: International Conference on Malignant Lymphoma 2025; June 17-21, 2025. Abstract LBA3.
  22. Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307-2315.
  23. Goldfinger M, Cooper DL. Refractory DLBCL: challenges and treatment. Clin Lymphoma Myeloma Leuk. 2022;22:140-148.
  24. Thieblemont C, Karimi YH, Ghesquieres H, et al. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38:2653-2662. Falchi M, Clausen M, Offner F, et al. Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data. J Clin Oncol. 2023;41:7519. 
  25. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220-2231.
  26. Cartron G, Houot R, Al Tabaa Y, et al. Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study. Nat Cancer. 2025;6:1173-1183.
  27. Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22:790-800.
  28. Bartlett NL, Hahn U, Kim WS, et al. Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma. Future Oncol. 2025;21:1965-1983.
  29. Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7:e511-e522.
  30. Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142:141-145.
  31. Westin J, Jacobson C, Chavez JC, et al. PB2319: ZUMA-23: a global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma. Hemasphere. 2023;7(suppl):e3278692.
  32. Falchi L, Clausen M, Offner F, et al. Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data. Presented at: American Society of Clinical Oncology Annual Meeting 2023; June 2-6, 2023. Abstract 7519.
  33. Falchi L, Jardin F, Haioun C, et al. Glofitamab (glofit) plus R-CHOP has a favorable safety profile and induces high response rates in patients with previously untreated (1L) large B-cell lymphoma (LBCL) defined as high risk by circulating tumor DNA (ctDNA) dynamics: preliminary safety and efficacy results. Presented at: American Society of Hematology Annual Meeting 2023; December 9-12, 2023. Abstract 858.
  34. Vermaat JSP, Brody J, Duras J, et al. Results from the Epcore NHL-2 trial arm 8: epcoritamab SC + R-mini-CHOP leads to high complete metabolic response rates in patients with previously untreated diffuse large B-cell lymphoma ineligible for full-dose R-CHOP. Presented at: American Society for Transplantation and Cellular Therapy Annual Meeting 2024; February 21-24, 2024. Abstract 489.
  35. Topp M, Tani M, Dickinson M, et al. Glofitamab combined with R-CHOP or Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): final results from the NP40126 study. Presented at: International Conference on Malignant Lymphoma 2025; June 17-21, 2025. Abstract 280.
  36. Hutchings M, Balari AS, Bosch F, et al. Glofitamab in combination with polatuzumab vedotin maintains durable responses and a manageable safety profile in patients with heavily pre-treated relapsed/refractory (R/R) large B-cell lymphoma (LBCL) including high-grade B-cell lymphoma (HGBCL): extended follow-up of a phase Ib/II study. Blood. 2024;144(suppl 1):988.
  37. Alderuccio JP, Okada C, Crochet G, et al. ABCL-777: initial results from LOTIS-7: a phase 1b study of loncastuximab tesirine plus glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Clin Lymphoma Myeloma Leuk. 2024;25(suppl 1):S758.
  38. Hutchings M, Dickinson MJ, Gritii G, et al. Englumafusp alfa (CD19-4-1BBL) combined with glofitamab is safe and efficacious in patients with R/R B-NHL: extended follow up analysis of the dose-escalation part of phase 1 trial BP41072. Blood. 2024;144(suppl 1):990.
  39. Gaballa S, Hou JZ, Cho SG, et al. Evaluation of AZD0486, a novel CD19xCD3 T-cell engager, in relapsed/refractory diffuse large B-cell lymphoma in an ongoing first-in-human phase 1 study: high complete responses seen in CAR-T-naive and CAR-T-exposed patients. Blood. 2024;144(suppl 1):868.
  40. Kim TM, Hou J-Z, Gaballa S, et al. Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–negative complete responses in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies. Presented at: American Society of Hematology Annual Meeting 2025; December 6-9, 2025. Abstract 5514.
  41. Chavez JC, Nastoupil LJ, Morschhauser F, et al. Efficacy and safety of golcadomide, a novel cereblon E3 ligase modulator (CELMoD) agent, combined with rituximab in a phase 1/2 open-label study of patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2023;142(suppl 1):4496.
  42. Michot JM, Morschhauser F, Ferrari S, et al. Longer follow-up of golcadomide (GOLCA), a cereblon E3 ligase modulator (CELMoD™) agent ± rituximab (RTX), in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Presented at: American Society of Hematology Annual Meeting 2024; December 7-10, 2024. Abstract 869.
  43. Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:1285-1295.
  44. Davies A, Caddy J, Mercer K, et al. Acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) as first line therapy for patients with diffuse large B-cell lymphoma (DLBCL): the Accept phase Ib/II single arm study. Presented at: American Society of Hematology Annual Meeting 2020; December 5-8, 2020. Abstract 1185.
  45. Xu P, Shi Z, Li F, et al. Zanubrutinib plus lenalidomide and rituximab versus R‐miniCHOP in unfit or frail patients with newly diagnosed diffuse large b‐cell lymphoma aged 70 years or older. Presented at: International Conference on Malignant Lymphoma 2025; June 17-21, 2025. Abstract LBA2. Xu PP, Zhu Y, Shi ZY, et al. A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma. Blood. 2025;146:2561-2573.
  46. Reidell PA, Kwon M, Dickinson MJ, et al. Rapcabtagene autoleucel (YTB323) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): phase II trial clinical update. Blood. 2024;144(suppl 1):67.
  47. Shah N, Maziarz R, Jacobson C, et al. Tandem CD20-CD19-directed non-cryopreserved CAR T cells - zamtocabtagene autoleucel (zamto-cel) in patients with relapsed/refractory diffuse large B cell lymphoma - interim results from a phase 2 pivotal study (DALY II USA). Transplantation and Cellular Therapy. 2025;31(suppl):S34.
  48. Kersten MJ, Saevels K, Willems E, et al. Atalanta-1: a phase 1/2 trial of GLPG5101, a fresh, stem-like, early memory CD19 CAR T-cell therapy with a 7-day vein-to-vein time, for the treatment of relapsed/refractory non-Hodgkin lymphoma. Blood. 2024;144(suppl 1):93.
  49. Dahiya S, Ulrickson M, Topp M, et al. A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL). J Clin Oncol. 2025;43:7003-7003.
  50. Patel K, Rhodes J, Mountjoy L, et al. A global phase 1B study of JNJ-90014496, a CD19/CD20 bi-specific chimeric antigen receptor (CAR) T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Presented at: European Hematology Association Annual Meeting 2025; June 12-15, 2025. Abstract S239.
  51. Svoboda J, Landsburg DJ, Gerson J, et al. Enhanced CAR T-cell therapy for lymphoma after previous failure. N Engl J Med. 2025;392:1824-1835.  
  52. Locke FL, Munoz JL, Tees MT, et al. Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel/ALLO-501 in relapsed/refractory large B-cell lymphoma: phase I experience from the ALPHA2/ALPHA clinical studies. J Clin Oncol. 2025;43:1695-1705.  
  53. Roschewski M, Kurtz DM, Westin JR, et al. Remission assessment by circulating tumor DNA in large B-cell lymphoma. J Clin Oncol. 2025;43:3652-3661.
  54. Westin JR, Herrera AF, Lynch R, et al. ALPHA3, a pivotal phase 2 study of first-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma and minimal residual disease after response to standard therapy. Blood. 2024;144(suppl 1):3132.1.